第一章 中國人體器官捐獻 1 一、機構(gòu)和隊伍建設(shè)情況 1 二、志愿登記情況 3 三、器官捐獻情況 5 四、相關(guān)工作開展 7 五、工作展望 9 第二章 中國人體捐獻器官獲取 10 一、人體捐獻器官獲取體系建設(shè)與發(fā)展 11 二、OPO機構(gòu)分布與建設(shè)情況 12 三、器官捐獻情況 13 四、器官獲取與利用情況 14 五、捐獻器官質(zhì)量情況 16 六、特點與展望 18 第三章 中國人體器官分配與共享 20 一、中國移植醫(yī)療機構(gòu)分布 22 二、人體器官捐獻情況 22 三、移植等待者情況 24 四、人體器官分配與共享政策實施效果 28 五、特點與展望 30 第四章 中國肝臟移植 32 一、肝臟移植醫(yī)療機構(gòu)分布 33 二、肝臟移植受體人口特征 35 三、肝臟移植質(zhì)量安全分析 36 四、特點與展望 39 第五章 中國腎臟移植 41 一、腎臟移植醫(yī)療機構(gòu)分布 42 二、腎臟移植受體人口特征 48 三、腎臟移植質(zhì)量安全分析 49 四、特點與展望 51 第六章 中國心臟移植 53 一、心臟移植醫(yī)療機構(gòu)分布 53 二、心臟移植受體人口特征 56 三、心臟移植質(zhì)量安全分析 57 四、特點與展望 59 第七章 中國肺臟移植 61 一、肺臟移植醫(yī)療機構(gòu)分布 62 二、肺臟移植受體人口特征 64 三、肺臟移植質(zhì)量安全分析 66 四、特點與展望 70 第八章 中國器官移植技術(shù)進展與創(chuàng)新 73 一、劈離式肝移植關(guān)鍵技術(shù)體系建立和推廣 73 二、甲胎蛋白-谷氨酰轉(zhuǎn)肽酶-杭州標準評分（AFP-GGT- Hangzhou scoring system，AGH評分）是肝細胞癌患者 肝移植術(shù)后無病生存和靶向治療效果的預測指標 75 三、融合雙分子標志物的肝癌肝移植患者分類新標準 79 四、天然高分子生物肝材料治療多器官功能衰竭核心技術(shù) 體系的建立與應(yīng)用 80 五、基于基因模型指導肝移植術(shù)后抗排異反應(yīng)精準給藥方案 82 六、達芬奇機器人輔助腹腔鏡技術(shù)在腎移植中的應(yīng)用 83 七、人工血管保護外鞘預防移植腎動脈扭折的療效 86 八、六基因編輯豬-恒河猴異種腎臟移植 88 九、國內(nèi)首組嬰幼兒供腎給嬰幼兒腎移植37例 90 十、無缺血心臟移植 91 十一、一種全新的心肌活檢技術(shù)在心臟移植術(shù)后的應(yīng)用 92 十二、基于機器學習的肺移植患者預后模型 94 十三、機器人輔助微創(chuàng)入路單肺移植手術(shù) 95 十四、供體來源游離DNA在肺移植術(shù)后排異反應(yīng) 診斷中的應(yīng)用 97 索 引 99 Contents Chapter 1 Human Organ Donation in China 101 1.1 Organizations and team building 102 1.2 Registration of human organ donation volunteers 105 1.3 Organ donation in China 107 1.4 Progress of related work 109 1.5 Future outlook 113 Chapter 2 Donated Organ Procurement in China 115 2.1 Development and construction of human donated organ procurement system 116 2.2 Distribution and construction of OPOs 118 2.3 Organ donation in China 119 2.4 Procurement and utilization of organs 121 2.5 Quality of donor organs 123 2.6 Features and future outlook 125 Chapter 3 Human Organ Allocation and Sharing in China 129 3.1 Distribution of transplant hospitals in China 132 3.2 Overview of human organ donation 133 3.3 Patients waiting for organ transplantation 135 3.4 Policy implementation efficacy in organ allocation and sharing 140 3.5 Feature and future outlook 142 Chapter 4 Liver Transplantation in China 145 4.1 Distribution of medical institutions qualified for liver transplantation 146 4.2 Demographic characteristics of liver transplant recipients 149 4.3 Quality and safety analysis of liver transplantation 150 4.4 Feature and future outlook 153 Chapter 5 Kidney Transplantation in China 156 5.1 Distribution of medical institutions qualified for kidney transplantation 157 5.2 Demographic characteristics of kidney transplant recipients 165 5.3 Quality and safety analysis of kidney transplantation 166 5.4 Feature and future outlook 169 Chapter 6 Heart Transplantation in China 172 6.1 Distribution of medical institutions qualified for heart transplantation 173 6.2 Demographic characteristics of heart transplant recipients 175 6.3 Quality and safety analysis of heart transplantation 177 6.4 Feature and future outlook 179 Chapter 7 Lung Transplantation in China 183 7.1 Distribution of medical institutions qualified for lung transplantation 184 7.2 Demographic characteristics of lung transplant recipients 187 7.3 Quality and safety analysis of lung transplantation 190 7.4 Feature and future outlook 195 Chapter 8 The Development of Technologies and Innovations for Organ Transplantation in China 199 8.1 Establishment and promotion of key technical system for split liver transplantation 199 8.2 The AGH score is a predictor of disease-free survival and targeted therapy efficacy after liver transplantation in patients with hepatocellular carcinoma 202 8.3 A novel stratification integrating dual biomarkers in liver transplantation for hepatocellular carcinoma 206 8.4 Establishment and application of core technology system for the treatment of multiple organ failure with natural polymer biological liver materials 208 8.5 Genotype-guided model used for precise anti-rejection therapy after liver transplantation 211 8.6 Application of Da Vinci robot-assisted laparoscopy in kidney transplantation 213 8.7 The utilization of an artificial protective external vascular sheath in renal transplantation represents a novel technological advancement aimed at preventing graft artery kinking 217 8.8 Six-genes edited porcine-rhesus kidney xenotran-splantation 219 8.9 The first group of 37 cases of kidney transplantation for infants and young children in China 221 8.10 Ischemia-free heart transplantation 224 8.11 A novel myocardial biopsy technique after heart transplantation 225 8.12 A machine learning based prognostic model for lung transplant patients 228 8.13 Robot-assisted lung transplantation 230 8.14 Application of donor-derived cell-free DNA in diagnosing rejection after lung transplantation 232
鄂公網(wǎng)安備 42010302001612號 